Kasumi Masuda1, Hiroki Taenaka1, Toshihiko Asanuma1, Satoshi Nakatani2. 1. Department of Functional Diagnostics, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka, 565-0871, Japan. 2. Department of Functional Diagnostics, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka, 565-0871, Japan. nakatani@sahs.med.osaka-u.ac.jp.
Abstract
OBJECTIVE: Losartan, an angiotensin II receptor blocker (ARB), has been reported to promote sodium excretion and show an enhanced antihypertensive effect when used in combination with hydrochlorothiazide (HCTZ). We investigated the effects of losartan monotherapy and combination therapy together with HCTZ on cardiac function in hypertensive rats using echocardiography. METHODS: Spontaneously hypertensive rats (n = 21) fed on high-salt diet (8 % NaCl) for 13 weeks were randomly assigned to rats without medication (HS, n = 7), those medicated with ARB (ARB, losartan 30 mg/kg/day, n = 8), and those with ARB and HCTZ (ARB + HCTZ, losartan 30 mg/kg/day + HCTZ 10 mg/kg/day, n = 6). Blood pressure measurements and echocardiography were performed at 13, 17, and 29 weeks of age. After the end of the protocol, the proportion of cardiac muscle fibrosis was measured histologically. RESULTS: In the HS group, blood pressure and left ventricular mass/body weight (LV mass/BW) increased, and % fractional shortening (%FS) and early diastolic mitral annular velocity (e') decreased significantly with age. In the ARB group, although blood pressure and %FS were maintained, LV mass/BW increased with age as in the HS group, and e' decreased. In the ARB + HCTZ group, blood pressure decreased and LV mass/BW, %FS, and e' were maintained. The progression of myocardial fibrosis was clearly prevented in rats treated with ARB. CONCLUSION: ARB was shown to inhibit systolic disorder and myocardial fibrosis in hypertensive rats. Combination therapy proved to be more effective than monotherapy and is also effective in inhibiting diastolic disorders.
OBJECTIVE:Losartan, an angiotensin II receptor blocker (ARB), has been reported to promote sodium excretion and show an enhanced antihypertensive effect when used in combination with hydrochlorothiazide (HCTZ). We investigated the effects of losartan monotherapy and combination therapy together with HCTZ on cardiac function in hypertensiverats using echocardiography. METHODS: Spontaneously hypertensiverats (n = 21) fed on high-salt diet (8 % NaCl) for 13 weeks were randomly assigned to rats without medication (HS, n = 7), those medicated with ARB (ARB, losartan 30 mg/kg/day, n = 8), and those with ARB and HCTZ (ARB + HCTZ, losartan 30 mg/kg/day + HCTZ 10 mg/kg/day, n = 6). Blood pressure measurements and echocardiography were performed at 13, 17, and 29 weeks of age. After the end of the protocol, the proportion of cardiac muscle fibrosis was measured histologically. RESULTS: In the HS group, blood pressure and left ventricular mass/body weight (LV mass/BW) increased, and % fractional shortening (%FS) and early diastolic mitral annular velocity (e') decreased significantly with age. In the ARB group, although blood pressure and %FS were maintained, LV mass/BW increased with age as in the HS group, and e' decreased. In the ARB + HCTZ group, blood pressure decreased and LV mass/BW, %FS, and e' were maintained. The progression of myocardial fibrosis was clearly prevented in rats treated with ARB. CONCLUSION: ARB was shown to inhibit systolic disorder and myocardial fibrosis in hypertensiverats. Combination therapy proved to be more effective than monotherapy and is also effective in inhibiting diastolic disorders.
Entities:
Keywords:
Angiotensin II receptor blocker; Cardiac function; Echocardiography; Hypertension
Authors: S R Ommen; R A Nishimura; C P Appleton; F A Miller; J K Oh; M M Redfield; A J Tajik Journal: Circulation Date: 2000-10-10 Impact factor: 29.690
Authors: Peter M Okin; Darcy A Hille; Sverre E Kjeldsen; Lars H Lindholm; Jonathan M Edelman; Björn Dahlöf; Richard B Devereux Journal: Am J Hypertens Date: 2010-04-15 Impact factor: 2.689
Authors: Tina Gröholm; Piet Finckenberg; Eeva Palojoki; Antti Saraste; Tom Bäcklund; Anders Eriksson; Mika Laine; Eero Mervaala; Ilkka Tikkanen Journal: Hypertens Res Date: 2004-08 Impact factor: 3.872
Authors: Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Markku S Nieminen; Steven Snapinn; Katherine E Harris; Peter Aurup; Jonathan M Edelman; Hans Wedel; Lars H Lindholm; Björn Dahlöf Journal: JAMA Date: 2004-11-17 Impact factor: 56.272
Authors: Richard B Devereux; Kristian Wachtell; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine Harris; Peter Aurup; Björn Dahlöf Journal: JAMA Date: 2004-11-17 Impact factor: 56.272